Akcea Therapeutics Inc
Most Recent
Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday
Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.
Why Citius Pharmaceuticals Stock Rose 31% in Week Ended July 13
In the week ended July 13, Citius Pharmaceuticals (CTXR) stock rose 31% to $3.09, from $2.35 on July 6. Since July 10, it has grown consistently.
Must-Know Developments for Ionis Pharmaceuticals in 2018
On February 20, 2018, Ionis announced that the company has licensed the drug IONIS-AZ5-2.5Rx to AstraZeneca (AZN).
Key Updates on Akcea Therapeutics’ Volanesorsen
Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug for the treatment of familial chylomicronemia syndrome (or FCS) and familial partial lipodystrophy (or FPL).
Exploring the Financial Performance of Akcea Therapeutics
In 2017, Akcea Therapeutics (AKCA) generated total revenue of $55.2 million.
A Look at Akcea Therapeutics’ Product Pipeline
Akcea Therapeutics’ (AKCA) Volanesorsen is currently under review in the United States, the European Union, and Canada.
Analysts’ Recommendations for Akcea and Its Peers in March
Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat many cardiometabolic diseases.